Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Rating of “Hold” from Analysts

Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) have been given an average recommendation of “Hold” by the five brokerages that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $4.50.

A number of brokerages have recently weighed in on HRTX. Zacks Research lowered Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, April 27th. HC Wainwright restated a “buy” rating on shares of Heron Therapeutics in a research note on Monday, May 11th. Wall Street Zen lowered Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Tuesday, April 21st.

Heron Therapeutics Price Performance

Shares of NASDAQ HRTX opened at $0.86 on Friday. Heron Therapeutics has a fifty-two week low of $0.74 and a fifty-two week high of $2.30. The company has a market cap of $162.55 million, a PE ratio of -4.77 and a beta of 1.70. The company has a debt-to-equity ratio of 17.51, a quick ratio of 1.51 and a current ratio of 2.53. The business has a 50-day simple moving average of $0.93 and a two-hundred day simple moving average of $1.13.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Heron Therapeutics had a negative return on equity of 7,747.30% and a negative net margin of 20.53%.The business had revenue of $34.71 million for the quarter, compared to analysts’ expectations of $36.72 million. As a group, equities analysts expect that Heron Therapeutics will post -0.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Bank of America Corp DE increased its holdings in shares of Heron Therapeutics by 19.7% in the first quarter. Bank of America Corp DE now owns 160,979 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 26,534 shares during the period. Excelsior Advisor Network LLC acquired a new position in shares of Heron Therapeutics in the first quarter valued at about $229,000. Orbimed Advisors LLC acquired a new position in shares of Heron Therapeutics in the first quarter valued at about $7,855,000. Pale Fire Capital SE increased its holdings in shares of Heron Therapeutics by 84.8% in the first quarter. Pale Fire Capital SE now owns 2,716,328 shares of the biotechnology company’s stock valued at $2,173,000 after purchasing an additional 1,246,673 shares during the period. Finally, HORAN Wealth LLC acquired a new position in shares of Heron Therapeutics in the first quarter valued at about $33,000. 80.01% of the stock is owned by institutional investors and hedge funds.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.